Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-26

FDA Approved: PANCREAZE — Supplemental Application (VIVUS LLC)

View source ↗

Summary

The FDA approved a supplemental application for Pancreaze (pancrelipase) from VIVUS LLC, updating its labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pancreaze (pancrelipase)

Snippet

SUPPL AP for PANCREAZE (PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE)